

THE UNIVERSITY OF MICHIGAN  
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Project Agreements with the University of Michigan

Action Requested: Authorization to enter into or amend Agreements

Preamble:

Statutory conflicts of interest situations were identified by the Office of Research and Sponsored Projects while reviewing Proposal Approval Forms that then triggered a review by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved at time of award.

These proposed project (e.g., research, sponsored activity, and/or subcontract) agreements (“Agreement”) and/or amendments to Agreements (“Amendments”) fall under the State of Michigan Conflict of Interest Statute because University of Michigan (“University”) employees have activities, relationships, or interests in the companies as described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents (“Regents”) of the University and approved in advance by a 2/3 vote.

Agreement Terms:

The terms of the Agreements and/or Amendments conform to University policy. The funding support will not exceed the amount reported in Attachment A for each Agreement and/or Amendment. Since projects are often amended, these Agreements and/or Amendments include provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreements and/or Amendments will provide support of investigator’s effort to use their expertise and University laboratories, as well as other University resources, to execute the projects as reported in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreements and Amendments were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into or amending the Agreements referenced in Attachment A.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Rebecca Cunningham', written in a cursive style.

Rebecca Cunningham  
Vice President for Research

December 2022

## Attachment A

### Project #1

<b>Amendment to Research Agreement between the University and ChromX Health Co., Ltd. Reviewed by the UMOR Conflict of Interest Review Committee</b>	
<b><u>Project Information</u></b>	
<b>Title:</b> Portable GC with argon discharge photoionization detector for breath analysis - additional funds	<b>U-M Project ID:</b> 23-PAF02760
<b>Direct Sponsor:</b> ChromX Health Co., Ltd.	
<b>Principal Investigator/Department:</b> Xudong Fan, Biomedical Engineering	
<b>Agreement Initially Approved by Regents:</b> July 15, 2021	
<b>Original Project Duration:</b> One (1) Year <b>Additional Time:</b> One (1) Year, Two (2) Months	<b>Initial Funding Support:</b> \$310,963 <b>Additional Funding:</b> \$48,232
<b>Purpose:</b> The purpose of this amendment is to add funds and time so that Dr. Fan may continue to develop portable GC devices with an argon discharge photoionization detector (PID) for breath analysis and conduct corresponding data analysis.	
<b><u>University Employee; University Title; Relationship with ChromX Health Co., Ltd.</u></b>	
<ul style="list-style-type: none"><li>• Xudong Fan; Professor, Biomedical Engineering; Partial Owner</li></ul>	

### Project #2

<b>SBIR Phase I Subcontract Agreement between the University and DASH Tech Integrated Circuits, Inc. Reviewed by the UMOR Conflict of Interest Review Committee</b>	
<b><u>Project Information</u></b>	
<b>Title:</b> DASH technology for Communication Acceleration	<b>U-M Project ID:</b> 23-PAF01629
<b>Direct Sponsor:</b> DASH Tech Integrated Circuits, Inc.	<b>Prime Sponsor:</b> Department of Defense Advanced Research Projects Agency
<b>Principal Investigator/Department:</b> David Blaauw, Electrical Engineering and Computer Science – Electrical and Computer Engineering (EECS-ECE) Division, Michigan Integrated Circuits Laboratory	
<b>Project Duration:</b> Two (2) Years	<b>Funding Support:</b> \$335,775
<b>Purpose:</b> The purpose of this project is to assist in refining the domain specific accelerator chip for communication applications and associated framework.	
<b><u>University Employee; University Title; Relationship with DASH Tech Integrated Circuits, Inc.</u></b>	
<ul style="list-style-type: none"><li>• David Blaauw; Professor, EECS-ECE Division; Partial Owner</li><li>• Hun Seok Kim; Associate Professor, EECS-ECE Division; Partial Owner</li></ul>	

### Project #3

<b>Research Agreement between the University and Eli Lilly and Company Reviewed by the Medical School Conflict of Interest Board</b>	
<b><u>Project Information</u></b>	
<b>Title:</b> Mechanisms Mediating the Hindbrain Control of Energy Balance - CNTF and Identifying CNS Circuits that Determine the Body Weight Set Point	<b>U-M Project ID:</b> 23-PAF02145
<b>Direct Sponsor:</b> Eli Lilly and Company	
<b>Principal Investigator/Department:</b> Randy Seeley, Surgery	
<b>Project Duration:</b> Four (4) Years	<b>Funding Support:</b> \$3,955,010
<b>Purpose:</b> The purpose of this project is to define potential mechanisms to target systems for weight loss therapies using a modality entirely distinct from the pharmacological tools currently available.	
<b><u>University Employee; University Title; Relationship with Eli Lilly and Company</u></b>	
<ul style="list-style-type: none"><li>• Marschall Runge; Executive Vice President for Medical Affairs and Dean of the Medical School; Board of Directors Member</li></ul>	

### Project #4

<b>Amendment to Research Agreement between the University and Eli Lilly and Company Reviewed by the Medical School Conflict of Interest Board</b>	
<b><u>Project Information</u></b>	
<b>Title:</b> CKD-Organoids-Amendment1	<b>U-M Project ID:</b> 23-PAF02188
<b>Direct Sponsor:</b> Eli Lilly and Company	
<b>Principal Investigator/Department:</b> Matthias Kretzler, Internal Medicine – Nephrology	
<b>Agreement Initially Approved by the Regents:</b> December 3, 2020	
<b>Original Project Duration:</b> Two (2) years <b>Additional Time:</b> One (1) Year	<b>Initial Funding Support:</b> \$502,862 <b>Additional Funding Support:</b> \$415,501
<b>Purpose:</b> The purpose of this amendment is to add funds and time so that Dr. Kretzler may continue to explore drug compounds of interest in kidney organoids modelling human kidney disease conditions.	
<b><u>University Employee; University Title; Relationship with Eli Lilly and Company</u></b>	
<ul style="list-style-type: none"><li>• Marschall Runge; Executive Vice President for Medical Affairs and Dean of the Medical School; Board of Directors Member</li></ul>	

### Project #5

<b>Research Agreement between the University and Eli Lilly and Company Reviewed by the Medical School Conflict of Interest Board</b>	
<b><u>Project Information</u></b>	
<b>Title:</b> Eli Lilly - Target Identification	<b>U-M Project ID:</b> 23-PAF02194
<b>Direct Sponsor:</b> Eli Lilly and Company	
<b>Principal Investigator/Department:</b> Matthias Kretzler, Internal Medicine – Nephrology	
<b>Project Duration:</b> One (1) Year	<b>Funding Support:</b> \$167,894
<b>Purpose:</b> The purpose of this project is to identify novel drug targets using bioinformatics and computational approaches.	
<b><u>University Employee; University Title; Relationship with Eli Lilly and Company</u></b>	
<ul style="list-style-type: none"><li>● Marschall Runge; Executive Vice President for Medical Affairs and Dean of the Medical School; Board of Directors Member</li></ul>	

### Project #6

<b>Subcontract Agreement between the University and EVOQ Therapeutics LLC Reviewed by the UMOR Conflict of Interest Review Committee</b>	
<b><u>Project Information</u></b>	
<b>Title:</b> New Approach for Immune Modulation Against T1D	<b>U-M Project ID:</b> 22-PAF05916
<b>Direct Sponsor:</b> EVOQ Therapeutics LLC	<b>Prime Sponsor:</b> Juvenile Diabetes Research Foundation International (JDRF)
<b>Principal Investigator/Department:</b> James Moon, Pharmaceutical Sciences	
<b>Project Duration:</b> Two (2) Years, Nine (9) Months	<b>Funding Support:</b> \$300,000
<b>Purpose:</b> The purpose of this project is to improve the peptide vaccine delivery for in vivo animal studies applying the nanodisc technology as a peptide delivery platform.	
<b><u>University Employee; University Title; Relationship with EVOQ Therapeutics LLC</u></b>	
<ul style="list-style-type: none"><li>● James Moon; Professor, Pharmaceutical Sciences; Partial Owner</li><li>● Anna Schwendeman; Professor, Pharmaceutical Sciences; Partial Owner</li></ul>	

**Project #7**

**STTR Phase II Subcontract Agreement between the University and Ulendo Technologies Inc. (formerly known as S2A Technologies LLC)  
Reviewed by the UMOR Conflict of Interest Review Committee**

**Project Information**

**Title:** Auto-calibration Techniques to Enable Commercial Scale-up of Software-based Vibration Compensation for 3D Printers

**U-M Project ID:** 22-PAF08218

**Direct Sponsor:** Ulendo Technologies Inc.

**Prime Sponsor:** National Science Foundation

**Principal Investigator/Department:** Daniel Cooper, Mechanical Engineering

**Project Duration:** Two (2) Years

**Funding Support:** \$324,978

**Purpose:** The purpose of this project is to develop auto-calibration techniques for the Filtered B Splines (FBS) vibration compensation algorithm applied to 3D printers.

**University Employee; University Title; Relationship with Ulendo Technologies Inc.**

- Chinedum Okwudire; Associate Professor, Mechanical Engineering; Partial Owner